Table 2
Component: Lipidoid | Molecular weight: Not confirmed | Reported molar entry: Not recovered | Calculated mass: Not calculated
sales@dcchemicals.com
C12-200
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Table 2
Component: DSPC | Molecular weight: 790.15 | Reported molar entry: Not recovered | Calculated mass: Not calculated
Table 2
Component: Cholesterol | Molecular weight: 386.65 | Reported molar entry: Not recovered | Calculated mass: Not calculated
Table 2
Component: PEG lipid | Molecular weight: Not confirmed | Reported molar entry: Not recovered | Calculated mass: Not calculated
Table 3
Parameter: Organic phase | Reported procedure / limitation: C12-200, DSPC, cholesterol and mPEG2000-DMG were dissolved in 90% ethanol. | Source: Main Methods, Formulation of LNPs; retained prior extraction
Table 3
Parameter: Aqueous phase | Reported procedure / limitation: siRNA in 10 mM citrate buffer at pH 3. | Source: Main Methods, Formulation of LNPs; retained prior extraction
Table 3
Parameter: RNA loading | Reported procedure / limitation: Total lipid:siRNA 7:1 by mass. This refers to all lipid components together, not C12-200 alone. N/P was not reported in the retained formulation record. | Source: Main Methods, Formulation of LNPs; retained prior extraction
Table 3
Parameter: Mixing | Reported procedure / limitation: Lipid and siRNA streams were pumped at equivalent volumetric flow rates through a T-junction. Absolute flow rate was not recovered. | Source: Main Methods, Formulation of LNPs; retained prior extraction
Table 3
Parameter: Buffer exchange | Reported procedure / limitation: Dialysis against PBS containing 155 mM NaCl, 3 mM Na2HPO4 and 1 mM KH2PO4, pH 7.5. | Source: Main Methods, Formulation of LNPs; retained prior extraction
Table 3
Parameter: Experiment separation | Reported procedure / limitation: Cell-screening lipidoid/siRNA complexes used distinct mass ratios; those values are not the four-component in vivo LNP composition. | Source: Main Results, Figs.2–3
Table 4
Measurement / batch: Particle diameter | Reported result: Approximately 80 nm | Evidence context: Main Methods; retained prior extraction; LNP value, not neat-lipid specification
Table 4
Measurement / batch: siRNA entrapment | Reported result: Approximately 90%, assessed by RiboGreen | Evidence context: Main Methods; retained prior extraction
Table 4
Measurement / batch: N/P, PDI and apparent pKa | Reported result: No experiment-specific numerical values recovered in this review | Evidence context: Do not infer N/P from the total-lipid mass ratio or borrow values from later C12-200 studies
Table 5
Experiment and dose: Initial in vivo lipidoid screen C57BL/6 mice; single intravenous tail-vein administration; anti-FVII siRNA 3 mg/kg; 12 purified lipidoids; n=3 or 4 | Readout and comparator: Readout: 72 h Comparator: Other library members and serum FVII baseline | Result and source: The lead C12-200 emerged from a fixed-weight-composition screen. This initial screen is distinct from the optimized low-dose C12-200 experiments. Main Results, initial in vivo screen and Fig.3
Table 5
Experiment and dose: Low-dose Factor VII response C57BL/6 mice; intravenous anti-FVII siRNA in C12-200 LNP | Readout and comparator: Readout: Assay timing is experiment-specific; 48/72 h is not pooled into one time point Comparator: LNP01 reference; nontargeting siRNA control at 1 mg/kg | Result and source: Activity reported below 0.01 mg/kg siRNA; more than two orders of magnitude greater dose potency than the earlier LNP01 system. No exact ED50 is inferred from the abstract claim. Main Abstract and Results, Fig.3
Table 5
Experiment and dose: Duration of Factor VII suppression C57BL/6 mice; single intravenous administration of 0.1 or 1 mg/kg anti-FVII siRNA; n=3 | Readout and comparator: Readout: 24 h to approximately 35 days Comparator: Predose/baseline serum Factor VII | Result and source: Complete silencing at 24 h; Factor VII protein returned to baseline by approximately 20 days at 0.1 mg/kg and 35 days at 1 mg/kg. Main Results, Fig.4
Table 5
Experiment and dose: Five-target liver silencing Mouse liver; FVII, ApoB, PCSK9, XBP1 and SORT1 siRNAs; single intravenous administration; 0.2 mg/kg per siRNA, totaling 1 mg/kg; n=5 | Readout and comparator: Readout: 72 h Comparator: Saline and control-siRNA groups | Result and source: More than 65% silencing for each of the five target mRNAs. The reported 0.2 mg/kg is per target and must not be presented as the total mixture dose. Main Results, Fig.5
Table 5
Experiment and dose: Cellular uptake mechanism HeLa cells; fluorescent siRNA/C12-200; dextran, transferrin and cholera toxin B trafficking markers; EIPA and cytochalasin D inhibition experiments | Readout and comparator: Readout: Membrane actin ruffling observed after 15 min; uptake-assay timings depend on experiment Comparator: Marker colocalization and inhibitor controls | Result and source: Dextran colocalization, actin changes and inhibitor-sensitive uptake support a macropinocytosis-associated route in this cell model. They do not establish an exclusive uptake route in vivo. Main Results, Fig.6
Table 5
Experiment and dose: Hepatic TTR silencing in nonhuman primates Cynomolgus monkeys; anti-TTR siRNA 0.03, 0.1 or 0.3 mg/kg; 15-minute cephalic-vein infusion; n=3 per dose | Readout and comparator: Readout: 48 h liver biopsy Comparator: PBS and irrelevant-siRNA controls | Result and source: Dose-dependent and sequence-specific hepatic TTR mRNA knockdown. Exact percentage values are not transcribed from the inaccessible figure in this pass. Main Results, nonhuman-primate TTR experiment; NHP methods retained from prior extraction
Table 5
Experiment and dose: Reported mouse tolerability observations C12-200 siRNA LNP at 1 mg/kg in the reported mouse experiments | Readout and comparator: Readout: Study-specific observations Comparator: PBS/control measurements | Result and source: No reported indication of toxicity or body-weight change; liver chemistry results were assessed in the paper. This limited observation does not establish long-term or clinical safety. Main Results, Table1 and Fig.4 discussion